Gautheron Jérémie, Vucur Mihael, Reisinger Florian, Cardenas David Vargas, Roderburg Christoph, Koppe Christiane, Kreggenwinkel Karina, Schneider Anne Theres, Bartneck Matthias, Neumann Ulf Peter, Canbay Ali, Reeves Helen Louise, Luedde Mark, Tacke Frank, Trautwein Christian, Heikenwalder Mathias, Luedde Tom
Department of Gastroenterology, Digestive Diseases and Intensive Care Medicine (Department of Medicine III), University Hospital RWTH Aachen, Aachen, Germany Interdisciplinary Centre for Clinical Research Aachen, University Hospital RWTH Aachen, Aachen, Germany.
Department of Gastroenterology, Digestive Diseases and Intensive Care Medicine (Department of Medicine III), University Hospital RWTH Aachen, Aachen, Germany.
EMBO Mol Med. 2014 Aug;6(8):1062-74. doi: 10.15252/emmm.201403856.
Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease in Western countries and often progresses to non-alcoholic steatohepatitis (NASH) leading ultimately to liver fibrosis and liver cancer. The occurrence of hepatocyte cell death-so far characterized as hepatocyte apoptosis-represents a fundamental step from benign steatosis toward progressive steatohepatitis. In contrast, the function of RIP3-dependent "necroptosis" in NASH and NASH-induced fibrosis is currently unknown. We show that RIP3 is upregulated in human NASH and in a dietary mouse model of steatohepatitis. RIP3 mediates liver injury, inflammation, induction of hepatic progenitor cells/activated cholangiocytes, and liver fibrosis through a pathway suppressed by Caspase-8. This function of RIP3 is mediated by a positive feedback loop involving activation of Jun-(N)-terminal Kinase (JNK). Furthermore, RIP3-dependent JNK activation promotes the release of pro-inflammatory mediators like MCP-1, thereby attracting macrophages to the injured liver and further augmenting RIP3-dependent signaling, cell death, and liver fibrosis. Thus, RIP3-dependent necroptosis controls NASH-induced liver fibrosis. This pathway might represent a novel and specific target for pharmacological strategies in patients with NASH.
非酒精性脂肪性肝病(NAFLD)是西方国家最常见的肝脏疾病,常进展为非酒精性脂肪性肝炎(NASH),最终导致肝纤维化和肝癌。肝细胞死亡的发生——目前被认为是肝细胞凋亡——是从良性脂肪变性向进行性脂肪性肝炎转变的关键步骤。相比之下,RIP3依赖的“坏死性凋亡”在NASH及NASH诱导的肝纤维化中的作用目前尚不清楚。我们发现,RIP3在人类NASH以及饮食诱导的脂肪性肝炎小鼠模型中表达上调。RIP3通过一条被半胱天冬酶-8抑制的途径介导肝损伤、炎症、肝祖细胞/活化胆管细胞的诱导以及肝纤维化。RIP3的这一功能由一个涉及Jun-(N)-末端激酶(JNK)激活的正反馈回路介导。此外,RIP3依赖的JNK激活促进促炎介质如MCP-1的释放,从而吸引巨噬细胞至受损肝脏,进一步增强RIP3依赖的信号传导、细胞死亡及肝纤维化。因此,RIP3依赖的坏死性凋亡控制NASH诱导的肝纤维化。该途径可能是NASH患者药物治疗策略的一个新的特异性靶点。